What is Cerebrolysin?
Cerebrolysin is a standardized mixture of small peptides and amino acids made from pig brain and sold as a neurotrophic drug in Austria, Russia, China, and dozens of other countries. Unlike most research peptides it has real randomized trials: a 1,070 patient acute stroke trial (CASTA) missed its primary endpoint, a 208 patient rehabilitation trial (CARS) found better arm function at 90 days, and Cochrane reviews rate the dementia evidence very low certainty and the stroke evidence as showing no mortality benefit with a possible increase in non-fatal serious adverse events. It has never been submitted to or approved by FDA and has no approved or lawfully compounded source in the United States.
Cerebrolysin is an enzymatically digested porcine brain extract: a mixture of low molecular weight peptides (under 10 kDa) and free amino acids given by intravenous or intramuscular injection. It is also known as Cerebrolysin concentrate, Porcine brain derived peptide preparation, FPF 1070, Cerebrolysinum.
How does it work?
Cerebrolysin is proposed to mimic the effects of endogenous neurotrophic factors such as BDNF, NGF, and CNTF, supporting neuronal survival, neurite outgrowth, and neurogenesis, and reducing excitotoxicity and free radical damage after ischemia. Because it is an undefined mixture, no single active peptide has been identified and the neurotrophic hypothesis rests on cell culture and rodent models of ischemia and neurodegeneration rather than a confirmed molecular target in humans.
| Cluster | Cognitive and neuroprotective |
|---|---|
| Routes | Intravenous infusion (all major trials); Intramuscular injection (approved labeling in some countries for smaller volumes) |
| Conditions studied | Cognitive decline and nootropic use; Stroke recovery; Traumatic brain injury |
| Record | v3, reviewed, verified Sep 29, 2026 |
Cerebrolysin benefits: what the evidence shows
Multiple randomized placebo controlled trials exist, mostly industry supported and conducted in Europe and Asia. Acute ischemic stroke: CASTA (n = 1,070) found no difference on the combined primary endpoint at 90 days, with a post hoc trend in severe strokes. Post stroke rehabilitation: CARS (n = 208) found a large effect on Action Research Arm Test scores at day 90 (Mann-Whitney 0.71, 95% CI 0.63 to 0.79). The 2020 Cochrane review of 7 stroke trials (1,601 participants) found no difference in all-cause death (RR 0.90, 95% CI 0.61 to 1.32) and a possible increase in non-fatal serious adverse events (RR 2.15, 95% CI 1.01 to 4.55). Alzheimer's disease: a 2015 industry linked meta-analysis of 6 RCTs found a small cognitive benefit at 4 weeks (SMD minus 0.40) that was not significant at 6 months. Vascular dementia: the 2019 Cochrane review of 6 trials (597 participants) found small benefits rated very low certainty. Net: the grade is human RCT, but the effect is uncertain and likely small.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 6 | 3755 |
| Human observational studies | 0 | n/a |
| Animal studies | 0 | n/a |
| All indexed studies | 6 | 3,755 |
Human evidence
CASTA (2012): 1,070 patients with acute ischemic stroke randomized within 12 hours to 30 mL intravenous Cerebrolysin or saline daily for 10 days; the confirmatory combined endpoint (modified Rankin Scale, Barthel Index, NIHSS) at 90 days showed no significant difference, and a post hoc subgroup with NIHSS above 12 showed lower 90 day mortality (10.5% versus 20.2%). CARS (2016): 208 patients starting 24 to 72 hours after stroke, 30 mL daily for 21 days plus rehabilitation; Action Research Arm Test at day 90 favored Cerebrolysin with a Mann-Whitney estimator of 0.71. Alvarez et al. (2006): 279 patients with mild to moderate Alzheimer's disease randomized to 10, 30, or 60 mL or placebo for 12 weeks; only the 10 mL dose improved ADAS-cog at 24 weeks. Cochrane 2020 (7 trials, 1,601 participants) and Cochrane 2019 (6 trials, 597 participants) both judged the evidence to be low or very low certainty with high risk of bias and industry funding in most trials.
Animal evidence
Rodent models of focal ischemia, traumatic brain injury, and transgenic Alzheimer's disease report reduced infarct volume, less amyloid pathology, and improved behavioral recovery with Cerebrolysin, and cell culture work shows neurotrophic like effects on neuronal survival and neurite growth. These models informed the neurotrophic hypothesis but do not identify which peptides in the mixture are responsible.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA)2012 PMID 22282884 | Randomized, double blind, placebo controlled trial, treatment within 12 hours of onset, 90 day follow upn = 1,070 Adults with acute ischemic hemispheric stroke in Asia, on aspirin | No significant difference on the combined primary endpoint (modified Rankin Scale, Barthel Index, NIHSS) at 90 days; post hoc trend to benefit and lower mortality (10.5% versus 20.2%) in patients with NIHSS above 12 | Evidence: Human RCT evidence |
| Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial2016 PMID 26564102 | Randomized, double blind, placebo controlled multicenter trial, 21 days of treatment plus rehabilitation, 90 day follow upn = 208 Adults 24 to 72 hours after ischemic stroke entering early rehabilitation | Action Research Arm Test at day 90 favored Cerebrolysin (Mann-Whitney estimator 0.71, 95% CI 0.63 to 0.79); authors called the study exploratory and asked for confirmation | Evidence: Human RCT evidence |
| Cerebrolysin for acute ischaemic stroke (Cochrane review, 2020 update)2020 PMID 32662068 | Cochrane systematic review and meta-analysis of 7 randomized trialsn = 1,601 Adults with acute ischemic stroke treated within 48 hours of onset | No difference in all-cause death (RR 0.90, 95% CI 0.61 to 1.32, moderate certainty); possible increase in non-fatal serious adverse events (RR 2.15, 95% CI 1.01 to 4.55); most trials industry supported | Evidence: Human RCT evidence |
| A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease2006 PMID 16420392 | Randomized, double blind, placebo controlled dose ranging trial, 12 weeks of infusions, 24 week follow upn = 279 Adults with mild to moderate Alzheimer's disease | Only the 10 mL dose improved ADAS-cog at week 24 (p = 0.038); 30 and 60 mL improved global impression but not cognition; adverse events similar across groups | Evidence: Human RCT evidence |
| Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials2015 PMID 25832905 | Meta-analysis of 6 randomized double blind placebo controlled trials of 30 mL per day; manufacturer employees among the authorsAdults with mild to moderate Alzheimer's disease | Cognitive benefit at 4 weeks (SMD minus 0.40, 95% CI minus 0.66 to minus 0.13) not sustained at 6 months (SMD minus 0.37, 95% CI minus 0.90 to 0.16); global clinical change favored Cerebrolysin at both timepoints | Evidence: Human RCT evidence |
| Cerebrolysin for vascular dementia (Cochrane review, 2019 update)2019 PMID 31710397 | Cochrane systematic review and meta-analysis of 6 randomized trialsn = 597 Adults with mild to moderate vascular dementia, mostly in China and Russia | Small benefit on cognition (SMD 0.36, 95% CI 0.13 to 0.58) and global function (RR 2.69 for response) rated very low certainty; high risk of bias and industry funding; no new trials since 2013 | Evidence: Human RCT evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Cognitive decline and nootropic use | Evidence: Human RCT evidence | Small trials in stroke and dementia with mixed results; not FDA approved. |
| Stroke recovery | Evidence: Human RCT evidence | CASTA (n = 1,070) missed its primary endpoint; CARS (n = 208) favored cerebrolysin on arm function at 90 days; a 2020 Cochrane review found no effect on death; not FDA approved. |
| Traumatic brain injury | Evidence: Human RCT evidence | A prospective meta-analysis of the two CAPTAIN trials (n = 185) found a small to medium benefit on a combined functional and neuropsychological score at 30 and 90 days; not FDA approved and not part of US TBI guidelines. |
Is Cerebrolysin legal in the United States?
FDA and compounding status
Cerebrolysin is not an FDA approved drug, and no FDA approval or marketing application has been identified. As of the last verification date, it did not appear on any FDA 503A category list (Category 1, 2, 3 or the withdrawn list) or on the 503A bulks list. No USP monograph or approved drug containing it has been identified. That leaves it outside FDA's interim enforcement policy, with no identified lawful basis for a US compounding pharmacy to prepare it. Whether FDA treats this animal-brain-derived peptide mixture as a biological product is unconfirmed.
WADA status
Not WADA prohibited. Not named on the current prohibited list. Athletes should still confirm against the list in force for their season.
Regulatory timeline
No regulatory events recorded.
Full tracker for Cerebrolysin or the category-wide tracker.
Email me when Cerebrolysin's status changes
Email only. Alerts have not started yet; we will ask you to confirm before the first one. Unsubscribe any time.
What published studies of Cerebrolysin used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Trial regimens, all by intravenous infusion: 30 mL daily for 10 days starting within 12 hours of stroke (CASTA); 30 mL daily for 21 days starting 24 to 72 hours after stroke alongside rehabilitation (CARS); 10, 30, or 60 mL five days a week for 4 weeks then twice weekly for 8 weeks in Alzheimer's disease (Alvarez 2006). These are the regimens used in cited studies, not a recommendation, and none is approved in the United States.
Routes reported
| # | Route |
|---|---|
| 1 | Intravenous infusion (all major trials) |
| 2 | Intramuscular injection (approved labeling in some countries for smaller volumes) |
Cerebrolysin side effects
Side effects
| # | Reported side effect |
|---|---|
| 1 | Possible increase in non-fatal serious adverse events in acute stroke (RR 2.15, 95% CI 1.01 to 4.55 in the 2020 Cochrane review, more pronounced with the 30 mL for 10 days regimen) |
| 2 | No difference in all-cause death or total adverse events versus placebo in stroke trials |
| 3 | Adverse event rates similar to placebo in Alzheimer's disease trials (dizziness, headache, agitation, and feeling hot reported) |
| 4 | Injection site reactions and rare allergic reactions per non-US labeling |
| 5 | Rapid infusion can cause feeling hot, sweating, or dizziness per non-US labeling |
| 6 | Theoretical prion transmission concern from porcine brain source, not documented in humans |
Interactions
| # | Interaction |
|---|---|
| 1 | No formal human interaction studies published in the indexed literature |
| 2 | Non-US labeling advises caution with antidepressants and MAO inhibitors because of possible additive effects (basis not established in trials) |
| 3 | Non-US labeling advises against mixing in the same infusion with balanced amino acid solutions |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Epilepsy or seizure disorder per non-US labeling |
| 2 | Severe renal impairment per non-US labeling |
| 3 | Known hypersensitivity to any component |
| 4 | Pregnancy and breastfeeding (no controlled data) |
How do people access Cerebrolysin legally?
Typical cost: Not available through licensed channels in the United States. In countries where it is approved, pharmacy prices are roughly 30 to 80 USD per 10 mL ampoule, so a 10 to 20 day course of 30 mL daily costs roughly 900 to 4,800 USD in drug alone. Prices noted on the last verified date and vary by country.
Access options
Not available
Not legally available in the United States: no FDA approved product and no compounding pathway.
Outside the US
Prescription in countries where it is registered (Austria, Russia, China, and others), administered by infusion in a clinic.
Not available
Products imported or sold online for US use are unapproved drugs and are not verified for cold chain or authenticity.
Access paths are checked against public regulatory records. Products labeled research use only are never listed.
Compare Cerebrolysin
What's actually offered, and what that means for you
FDA has found a compounding pharmacy offering cerebrolysin anyway. [11]
Being offered does not change the legal status of cerebrolysin. Cerebrolysin is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound it. [7] [12]
What FDA found
- April 2020: FDA named cerebrolysin among the bulk substances a state-licensed 503A pharmacy compounded outside section 503A. [11]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [12] [13] [14] [15] [16] [17]
What that means for you
- A pharmacy that compounds cerebrolysin is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [13] [14]
- No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [17]
- State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [18]
- Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [19] [20]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [12]
- Insurance rarely covers it, so you usually pay cash.
If you're going ahead anyway
These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound cerebrolysin, with or without a prescription. [7]
Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [21] [22] [23]
What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [23] [24] [25]
Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [17] [26] [27] [28] [29] [30]
Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [17]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Questions to ask
- Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [21]
- Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [25]
- Pharmacy: Is this made for me on a prescription written in my name? [24]
- Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [23] [25]
- Prescriber: What is the legal basis for a pharmacy to compound cerebrolysin? Is it FDA approved or on the 503A bulks list? [7] [17]
- Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [25]
In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [18]
Frequently asked questions
Is Cerebrolysin legal in the United States?
No, not for prescription or sale. Cerebrolysin has never been submitted to or approved by FDA, it cannot be compounded because it is an undefined animal derived mixture rather than a bulk drug substance, and importing unapproved drugs for personal use is generally not permitted. It is a legitimately registered prescription drug in Austria, Russia, China, and many other countries, where it is given by infusion in clinical settings. [3] [7]
Does Cerebrolysin work for stroke?
The evidence is mixed. The largest trial, CASTA, randomized 1,070 acute stroke patients to 30 mL daily for 10 days or placebo and found no significant difference on its primary combined outcome at 90 days, with a post hoc trend toward benefit in severe strokes. The smaller CARS trial (n = 208) started treatment 1 to 3 days after stroke alongside rehabilitation and found better arm function at 90 days. The 2020 Cochrane review of 7 trials (1,601 participants) concluded that Cerebrolysin probably has little or no effect on death and may increase non-fatal serious adverse events. [1] [2] [3]
Does Cerebrolysin work for dementia or Alzheimer's disease?
Modestly at best, with low certainty. A 2015 meta-analysis of 6 randomized trials in mild to moderate Alzheimer's disease, co-authored by the manufacturer's staff, found a small cognitive benefit at 4 weeks (standardized mean difference minus 0.40) that was no longer significant at 6 months. The 2019 Cochrane review of 6 trials in vascular dementia (597 participants) found small improvements in cognition and global function but rated the evidence very low certainty because of bias, heterogeneity, and industry funding, and warned any benefit may be too small to matter clinically. [4] [5] [6]
What are the side effects of Cerebrolysin?
In trials, total adverse events and deaths were similar to placebo. The main safety signal is from the 2020 Cochrane stroke review, which found a possible increase in non-fatal serious adverse events (risk ratio 2.15, 95% CI 1.01 to 4.55), more pronounced with the 30 mL for 10 days regimen. Non-US labeling lists dizziness, headache, agitation, feeling hot with rapid infusion, and rare allergic reactions, and contraindicates it in epilepsy and severe kidney disease. Because it comes from pig brain there is a theoretical but undocumented prion concern. [3] [4]
How is Cerebrolysin given?
In the trials it was given by intravenous infusion in a clinic, in daily courses of about 10 to 21 days after stroke and in longer courses in Alzheimer's disease. Non-US labeling also allows intramuscular use. It is not a self injected product, and no regimen is approved in the United States. [1] [2] [4]
How much does Cerebrolysin cost?
There is no US price because it is not lawfully available here. In countries where it is registered, pharmacy prices run roughly 30 to 80 USD per 10 mL ampoule, so a course of 30 mL daily for 10 to 20 days costs roughly 900 to 4,800 USD in drug alone, before clinic and infusion fees. Prices were noted on the last verified date and vary widely by country. [3]
Is Cerebrolysin banned by WADA?
No. Section S0 of the WADA Prohibited List covers substances with no approval from any governmental health authority, and Cerebrolysin is an approved prescription drug in Austria and many other countries. It is not listed in any other section of the 2026 list or the 2027 list published in September 2026. Athletes should still confirm with their anti-doping organization, since list interpretations can change. [9] [10]
Cerebrolysin vs semax: which has better evidence?
Cerebrolysin, by a wide margin, though neither is FDA approved. Cerebrolysin has several indexed randomized placebo controlled trials, including a 1,070 patient stroke trial and Cochrane reviews, even if the results are mixed and low certainty. Semax has Russian clinical reports and no indexed randomized trial. On US access neither has a lawful pathway. News reports said the FDA advisory committee voted to recommend listing semax in July 2026, but FDA's own briefing recommended against listing, and FDA has not posted the vote or minutes; Cerebrolysin has no US pathway at all. [3] [8]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Heiss WD et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke 2012 (CASTA)PubMed 22282884, 2012
- [2]Muresanu DF et al. Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke 2016PubMed 26564102, 2016
- [3]Ziganshina LE, Abakumova T, Hoyle CH. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev 2020PubMed 32662068, 2020
- [4]Alvarez XA et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease. Eur J Neurol 2006PubMed 16420392, 2006
- [5]Gauthier S et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord 2015PubMed 25832905, 2015
- [6]Cui S et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev 2019PubMed 31710397, 2019
- [7]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [8]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [9]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [10]WADA 2027 Prohibited List (published September 21, 2026, in force January 1, 2027)WADA, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 29). Cerebrolysin: evidence, legality, and access. https://peptideagent.ai/peptides/cerebrolysin- HTML link
<a href="https://peptideagent.ai/peptides/cerebrolysin">Cerebrolysin: evidence, legality, and access</a>, PeptideAgent, updated September 29, 2026.